218 related articles for article (PubMed ID: 16444355)
21. Multiple endocrine neoplasia type 2.
Gertner ME; Kebebew E
Curr Treat Options Oncol; 2004 Aug; 5(4):315-25. PubMed ID: 15233908
[TBL] [Abstract][Full Text] [Related]
22. A nationwide clinical survey of patients with multiple endocrine neoplasia type 2 and familial medullary thyroid carcinoma in Japan.
Iihara M; Yamashita T; Okamoto T; Kanbe M; Yamazaki K; Egawa S; Yamaguchi K; Obara T
Jpn J Clin Oncol; 1997 Jun; 27(3):128-34. PubMed ID: 9255265
[TBL] [Abstract][Full Text] [Related]
23. Multiple endocrine neoplasia (MEN)--an overview and case report--patient with sporadic bilateral pheochromocytoma, hyperparathyroidism and marfanoid habitus.
Fassbender WJ; Krohn-Grimberghe B; Görtz B; Litzlbauer D; Stracke H; Raue F; Kaiser HE
Anticancer Res; 2000; 20(6C):4877-87. PubMed ID: 11205236
[TBL] [Abstract][Full Text] [Related]
24. Sporadic and familial medullary thyroid carcinoma: state of the art.
Moo-Young TA; Traugott AL; Moley JF
Surg Clin North Am; 2009 Oct; 89(5):1193-204. PubMed ID: 19836492
[TBL] [Abstract][Full Text] [Related]
25. Familial medullary thyroid carcinoma: not a distinct entity? Genotype-phenotype correlation in a large family.
Moers AM; Landsvater RM; Schaap C; Jansen-Schillhorn van Veen JM; de Valk IA; Blijham GH; Höppener JW; Vroom TM; van Amstel HK; Lips CJ
Am J Med; 1996 Dec; 101(6):635-41. PubMed ID: 9003111
[TBL] [Abstract][Full Text] [Related]
26. Rudolf-Virchow-Preis 1995. The role of RET proto-oncogene mutation analysis in the diagnosis of multiple endocrine neoplasia type 2 (MEN 2) gene carriers and in the discrimination of sporadic and familial medullary thyroid carcinomas and pheochromocytomas.
Komminoth P
Verh Dtsch Ges Pathol; 1995; 79():L-LV. PubMed ID: 8600671
[TBL] [Abstract][Full Text] [Related]
27. Very early detection of RET proto-oncogene mutation is crucial for preventive thyroidectomy in multiple endocrine neoplasia type 2 children: presence of C-cell malignant disease in asymptomatic carriers.
Sanso GE; Domene HM; Garcia R; Pusiol E; de M; Roque M; Ring A; Perinetti H; Elsner B; Iorcansky S; Barontini M
Cancer; 2002 Jan; 94(2):323-30. PubMed ID: 11900218
[TBL] [Abstract][Full Text] [Related]
28. Late diagnosis of type 2B multiple endocrine neoplasia (MEN 2B) in a 23 year-old patient.
Andrysiak-Mamos E; Sowińska-Przepiera E; Żochowska E; Kazimierczyk-Puchalska A; Syrenicz J; Lubikowski J; Birkenfeld B; Syrenicz A
Endokrynol Pol; 2011; 62(6):548-53. PubMed ID: 22144222
[TBL] [Abstract][Full Text] [Related]
29. Multiple endocrine neoplasia type 2.
Peczkowska M; Januszewicz A
Fam Cancer; 2005; 4(1):25-36. PubMed ID: 15883707
[TBL] [Abstract][Full Text] [Related]
30. Analysis of RET proto-oncogene abnormalities in patients with MEN 2A, MEN 2B, familial or sporadic medullary thyroid carcinoma.
Chiefari E; Russo D; Giuffrida D; Zampa GA; Meringolo D; Arturi F; Chiodini I; Bianchi D; Attard M; Trischitta V; Bruno R; Giannasio P; Pontecorvi A; Filetti S
J Endocrinol Invest; 1998 Jun; 21(6):358-64. PubMed ID: 9699127
[TBL] [Abstract][Full Text] [Related]
31. Multiple endocrine neoplasia, the old and the new: a mini review.
Pasquali D; Di Matteo FM; Renzullo A; Accardo G; Esposito D; Barbato F; Colantuoni V; Circelli L; Conzo G
G Chir; 2012; 33(11-12):370-3. PubMed ID: 23140918
[TBL] [Abstract][Full Text] [Related]
32. Genotype-phenotype relationship in multiple endocrine neoplasia type 2. Implications for clinical management.
Raue F; Frank-Raue K
Hormones (Athens); 2009; 8(1):23-8. PubMed ID: 19269918
[TBL] [Abstract][Full Text] [Related]
33. Molecular mechanisms of medullary thyroid carcinoma: current approaches in diagnosis and treatment.
Boikos SA; Stratakis CA
Histol Histopathol; 2008 Jan; 23(1):109-16. PubMed ID: 17952863
[TBL] [Abstract][Full Text] [Related]
34. [Results of treating medullary thyroid carcinoma: the differences between sporadic and inherited forms].
Wygoda Z; Włoch J; Gubała E; Wiench M; Jarzab B
Wiad Lek; 2001; 54 Suppl 1():422-31. PubMed ID: 12182060
[TBL] [Abstract][Full Text] [Related]
35. Role of the RET proto-oncogene in sporadic hyperparathyroidism and in hyperparathyroidism of multiple endocrine neoplasia type 2.
Pausova Z; Soliman E; Amizuka N; Janicic N; Konrad EM; Arnold A; Goltzman D; Hendy GN
J Clin Endocrinol Metab; 1996 Jul; 81(7):2711-8. PubMed ID: 8675600
[TBL] [Abstract][Full Text] [Related]
36. Distinction between sporadic and hereditary medullary thyroid carcinoma (MTC) by mutation analysis of the RET proto-oncogene. "Study Group Multiple Endocrine Neoplasia Austria (SMENA)".
Fink M; Weinhüsel A; Niederle B; Haas OA
Int J Cancer; 1996 Aug; 69(4):312-6. PubMed ID: 8797874
[TBL] [Abstract][Full Text] [Related]
37. [Polyadenomatoses: type 2 multiple endocrine neoplasms].
Conte-Devolx B; Niccoli-Sire P;
Presse Med; 2002 Aug; 31(26):1224-30. PubMed ID: 12212516
[TBL] [Abstract][Full Text] [Related]
38. Multiple endocrine neoplasia type 2A: case report.
Păun DL; Poiană C; Petriş R; Radian S; Miulescu RD; Constantinescu G; Orban C
Chirurgia (Bucur); 2013; 108(6):900-3. PubMed ID: 24331334
[TBL] [Abstract][Full Text] [Related]
39. RET proto-oncogene mutations in multiple endocrine neoplasia type 2 and medullary thyroid carcinoma.
Marsh DJ; Mulligan LM; Eng C
Horm Res; 1997; 47(4-6):168-78. PubMed ID: 9167949
[TBL] [Abstract][Full Text] [Related]
40. [Multiple endocrine neoplasia syndrome].
Shchepotin IB; Zotov AS
Vopr Onkol; 2005; 51(6):722-7. PubMed ID: 17037044
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
